• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » N-acetylcysteine Not Effective for Cannabis Use Disorder in Adults

N-acetylcysteine Not Effective for Cannabis Use Disorder in Adults

October 2, 2019
Brian Frankel, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Gray KM et al, Drug and Alcohol Dependence 2017;177:249–257

N-acetylcysteine (NAC) is an over-the-counter supplement related to the amino acid cysteine. In addition to its use as an antidote for acetaminophen poisoning, it has shown evidence of efficacy in some psychiatric disorders. For substance use disorders, its primary mechanism of action is the reversal of glutamate dysregulation, theoretically reducing vulnerability to relapse. A 2012 study of 116 adolescents with cannabis use disorder (CUD) found that subjects randomly assigned to 1200 mg of NAC were twice as likely to have cannabis-negative urines than those taking placebo. This most recent study attempted to replicate these findings in adults.

In this 12-week double-blind randomized controlled trial, 302 treatment-seeking adult participants diagnosed with CUD were randomized to placebo or 1200 mg NAC, both prescribed twice daily. The primary outcome was the percent likelihood of a negative urine cannabinoid test (UCT). UCTs were collected at baseline and twice weekly throughout the trial. Both groups also received a contingency management intervention (escalating cash payments to positively reinforce attendance and abstinence) and weekly medication counseling. The majority of the participants were white and male.

The results were discouraging: After 12 weeks, patients assigned to NAC submitted no more cannabis-free samples (22.3%) than those taking placebo (22.4%). However, a post-hoc analysis found that the younger participants in the trial (ages 18–21) were twice as likely to produce a negative UCT when assigned to the NAC group compared with placebo—although this finding did not reach statistical significance (p = 0.187). Though the medication was well tolerated, a major limitation of the study was poor medication adherence (73% adherence to NAC, 72% placebo), which was not problematic in the adolescent study (95% NAC, 93% placebo).

CATR’s Take
NAC does not appear to be effective for CUD in adults, though it’s possible that adolescents respond better to this supplement. Given that it is cheap and well tolerated (and that there are no effective alternatives), you might consider offering NAC to adolescents who are having difficulty cutting down their cannabis use.
Addiction Treatment
KEYWORDS addiction addiction-treatment cannabis marijuana substance-use-disorder
    Brian Frankel, MD

    The COMBINE Study: A Core Paper in the Treatment of AUD

    More from this author
    www.thecarlatreport.com
    Issue Date: October 2, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Alcohol Addiction, CATR, September/October 2019
    Primer: Evidence-Based Psychosocial Interventions for Substance Use Disorders
    Treating Alcohol Use Disorder
    Biomarkers of Alcohol Use
    N-acetylcysteine Not Effective for Cannabis Use Disorder in Adults
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.